Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

CorMedix Therapeutics announced interim results for the company’s ongoing real-world study of its DefenCath (taurolidine ...

Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong ...

After two dialysis patients died at a Kerala government hospital, concerns mount over infection and mortality risks in people ...

For many dialysis patients, the whole idea can feel extremely confusing and even a bit scary because the process isn't always explained clearly. Sometimes the patient themselves may not remember the ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

CorMedix is a promising biopharma firm in the catheter lock solution space. Continued success for its top products could fuel ...

CorMedix sees its revenue contracting significantly in 2026. CRMD shares crashed about 35% on the announcement today.

CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited ...

Preventogen™ eradicated Candida auris antibiotic-resistant strain by 99.99% at 30, 90 and 120 seconds with a formidable 5.61 log reduction. ST. LOUIS, MO / ACCESS Newswire / January 7, 2026 / ...

Officer Quas’Jon “Q” Flowers, 25, and a two-year veteran of the Albany Police Department, was diagnosed with advanced kidney ...

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year. ・The company expects adjusted EBITDA for 2026 to be between $100 million and ...